Corcept Therapeutics Incorporated’s New Drug Application for relacorilant as a treatment for hypertension secondary to hypercortisolism has been rejected by the U.S. Food and Drug Administration, which issued a Complete Response Letter citing insufficient evidence to support a favorable benefit-risk profile. The news sent Corcept’s stock sharply lower as investors digested the implications for its endocrine franchise and upcoming oncology filings.

What this reveals about relacorilant’s clinical positioning and regulatory limits

The Complete Response Letter marks a notable regulatory rebuff for a candidate that had been positioned as a follow-up to Korlym, Corcept Therapeutics Incorporated’s currently marketed treatment for endogenous Cushing’s syndrome. Unlike Korlym, which is associated with off-target effects due to its broad glucocorticoid receptor antagonism, relacorilant was developed to offer selective GR modulation, aiming to avoid progesterone receptor binding and associated side effects.

Relacorilant’s submission had been supported by data from two studies: GRACE, a pivotal Phase 3 trial with a randomized withdrawal design, and GRADIENT, a separate study that sought to confirm efficacy. The GRACE study met its primary endpoint, with patients showing improvements in blood pressure, glycemic control, and body weight compared to baseline. GRADIENT provided additional, though somewhat mixed, evidence across secondary endpoints.

However, the FDA’s determination suggests that the observed benefits—despite statistical significance—did not rise to the level of clear clinical efficacy required for approval. This reflects an increasingly high bar for hormonal disease therapeutics, especially in conditions like Cushing’s syndrome where symptomatic variability and trial heterogeneity can confound benefit-risk assessments.

Industry analysts note that relacorilant’s GRACE trial relied on surrogate measures like blood pressure reductions and metabolic markers rather than direct patient-reported outcome instruments. The agency’s insistence on more definitive proof of benefit points to a broader shift in regulatory expectations for endocrine therapies.

Why this weakens Corcept’s near-term growth narrative in endocrinology

Corcept Therapeutics Incorporated had positioned relacorilant as a commercial evolution of Korlym, targeting the same underlying indication with a cleaner safety profile. From a market perspective, relacorilant was projected to capture patients intolerant to Korlym’s side effects and expand the prescriber base with a more manageable risk profile.

The Complete Response Letter significantly delays that expansion, forcing Corcept Therapeutics Incorporated to reassess its development roadmap. Analysts had forecast a $300 million–$500 million peak revenue opportunity for relacorilant in hypercortisolism, under the assumption that the label would eventually include broader metabolic and cardiovascular indications. That thesis is now in question. In response to the FDA’s feedback, the company will need to design and execute another study or set of studies that can satisfy the regulator’s call for additional evidence—a process that could take several years and require significant investment.

The commercial implications are especially acute given that relacorilant represented the most advanced pipeline asset in Corcept Therapeutics Incorporated’s non-oncology portfolio. Without its approval, the company remains reliant on Korlym and faces growing pressure to monetize its broader cortisol modulator library across other disease areas.

How this shifts attention to Corcept’s oncology ambitions

Despite the regulatory setback in endocrinology, relacorilant remains under active review in a second indication—platinum-resistant ovarian cancer. Corcept Therapeutics Incorporated recently submitted a Marketing Authorization Application to the European Medicines Agency and has a Prescription Drug User Fee Act (PDUFA) action date of July 11, 2026, in the United States for this cancer use case.

In oncology, relacorilant is being developed in combination with nab-paclitaxel based on data from the ROSELLA trial. The combination demonstrated statistically significant improvement in progression-free survival and showed encouraging trends in overall survival. Unlike the hypercortisolism program, the oncology program’s endpoints—such as time to progression—are more clearly validated in regulatory precedent, and the patient population is both more homogeneous and more acutely ill.

This dual-track strategy means that Corcept Therapeutics Incorporated could still salvage meaningful value from relacorilant, albeit in a very different clinical context. If approved in oncology, relacorilant would address a large, high-need segment and help mitigate the commercial fallout from the CRL in endocrinology. It would also support Corcept’s narrative that selective glucocorticoid receptor modulation has utility beyond rare endocrine disorders and into the immunosuppressive tumor microenvironment.

What the CRL means for broader drug development in Cushing syndrome

Corcept Therapeutics Incorporated is not the only firm navigating difficult regulatory waters in the Cushing’s landscape. The condition’s complexity, ranging from ACTH-producing tumors to adrenal and ectopic sources, creates challenges in patient stratification and endpoint selection. The FDA has shown reluctance to grant broad indications without robust and repeatable signals across key clinical domains.

For future entrants in the Cushing space—particularly those developing new GR antagonists or steroidogenesis inhibitors—this decision sets a precedent. Even when a therapy demonstrates statistically significant improvements in surrogate measures, regulators may demand more holistic evidence of benefit, particularly if side effect profiles or off-target concerns are non-trivial.

This also raises the question of trial design evolution. Adaptive protocols, real-world evidence, and long-term follow-up data may become increasingly essential for sponsors seeking to navigate complex endocrine indications. Relacorilant’s CRL highlights that single-trial efficacy, even if nominally achieved, may no longer be sufficient if confounded by design limitations or ambiguous endpoint relevance.

What’s next for relacorilant and for Corcept’s regulatory playbook

Corcept Therapeutics Incorporated has publicly committed to meeting with the FDA as soon as possible to determine the optimal path forward. The company may need to pursue an additional registrational study or potentially conduct a real-world outcomes study that tracks long-term patient improvement under real clinical conditions. Depending on the feedback, the company might also consider biomarker-enriched subgroups or alternative primary endpoints.

There is also the question of global regulatory divergence. While the FDA has issued a CRL, the European Medicines Agency may adopt a more favorable stance if the same data package is retooled or supplemented. Corcept could potentially gain traction in ex-U.S. markets while addressing the FDA’s requirements in parallel. However, given the agency’s concerns around evidence of effectiveness, the hurdle for any health authority is now higher.

Internally, this decision will likely accelerate strategic prioritization within Corcept’s pipeline. The company has other programs in neurology and metabolic disorders, but none as far along as relacorilant. Investors and industry observers will now closely track how quickly the company can either remediate the CRL or extract value from its oncology filing to sustain momentum.

What clinicians and regulators will be watching next

Key developments to watch in the coming months include the outcome of Corcept Therapeutics Incorporated’s upcoming meeting with the U.S. Food and Drug Administration and any indications of a viable path to resubmission. The nature of the agency’s requested data—whether requiring an entirely new trial or additional analyses from existing studies—will shape the regulatory and commercial timeline for relacorilant in hypercortisolism.

Attention will also turn to the European Medicines Agency’s review of relacorilant in platinum-resistant ovarian cancer. Observers will assess whether the oncology data, which showed promising progression-free survival in combination with nab-paclitaxel, can validate the broader glucocorticoid receptor modulation strategy that underpins Corcept’s entire pipeline. A favorable EMA decision could partially offset the setback in endocrinology and reinforce the molecule’s value across therapeutic domains.

Competitive dynamics in the Cushing’s syndrome market are also likely to shift. Other drug developers targeting the same indication—particularly those working on next-generation cortisol biosynthesis inhibitors or adrenocorticotropic hormone (ACTH)-directed therapies—may use this regulatory pause to differentiate their own programs, either by emphasizing stronger efficacy data or leveraging narrower but clearer endpoints.

Finally, changes in how regulatory agencies evaluate benefit-risk trade-offs for endocrine disorders with high symptomatic variability will remain in focus. The relacorilant decision highlights an emerging demand for more holistic data that go beyond surrogate endpoints to demonstrate direct clinical relevance, especially in conditions where long-term management and quality-of-life improvements are central to therapeutic value.

For now, the Complete Response Letter for relacorilant is not merely a delay in approval. It serves as a clarifying moment for the field of cortisol biology and a reminder that precision in both trial design and endpoint selection remains essential for regulatory success in rare endocrine diseases.

  Corcept Therapeutics Incorporated, Cushing’s syndrome, EMA MAA, endocrine disorders, FDA rejection, glucocorticoid receptor antagonist, GRACE trial, GRADIENT trial, hypercortisolism, oncology, ovarian cancer, relacorilant, ROSELLA trial